

## What is claimed is:

1. A method for diagnosing the presence of cancer in a patient comprising:
- (a) determining levels of Lng108 in cells, tissues or 5 bodily fluids in a patient; and
  - (b) comparing the determined levels of Lng108 with levels of Lng108 in cells, tissues or bodily fluids from a normal human control, wherein a change in determined levels of Lng108 in said patient versus normal human control is associated with 10 the presence of cancer.
2. A method of diagnosing metastases of cancer in a patient comprising:
- (a) identifying a patient having cancer that is not known to have metastasized;
  - 15 (b) determining Lng108 levels in a sample of cells, tissues, or bodily fluid from said patient; and
  - (c) comparing the determined Lng108 levels with levels of Lng108 in cells, tissue, or bodily fluid of a normal human control, wherein an increase in determined Lng108 levels in 20 the patient versus the normal human control is associated with a cancer which has metastasized.
3. A method of staging cancer in a patient having cancer comprising:
- (a) identifying a patient having cancer;
  - 25 (b) determining Lng108 levels in a sample of cells, tissue, or bodily fluid from said patient; and
  - (c) comparing determined Lng108 levels with levels of Lng108 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in determined Lng108 levels in 30 said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the determined Lng108 levels is associated with a cancer which is regressing or in remission.
4. A method of monitoring cancer in a patient for the 35 onset of metastasis comprising:

(a) identifying a patient having cancer that is not known to have metastasized;

(b) periodically determining levels of Lng108 in samples of cells, tissues, or bodily fluid from said patient; and

5 (c) comparing the periodically determined Lng108 levels with levels of Lng108 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined Lng108 levels in the patient versus the normal human control is associated with a cancer which has  
10 metastasized.

5. A method of monitoring a change in stage of cancer in a patient comprising:

(a) identifying a patient having cancer;

(b) periodically determining levels of Lng108 in cells,  
15 tissues, or bodily fluid from said patient; and

(c) comparing the periodically determined Lng108 levels with levels of Lng108 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically determined Lng108 levels in the patient versus  
20 the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

6. A method of identifying potential therapeutic agents for use in imaging and treating cancer comprising screening  
25 molecules for an ability to bind to or decrease expression of Lng108 wherein the ability of a molecule to bind to Lng108 or decrease expression of Lng108 is indicative of the molecule being useful in imaging and treating cancer.

7. A method of imaging cancer in a patient comprising  
30 administering to the patient an antibody which specifically binds to Lng108.

8. The method of claim 7 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

9. A method of treating cancer in a patient comprising  
35 administering to the patient an antibody which specifically

binds to Lng108.

10. The method of claim 9 wherein the antibody is conjugated to a cytotoxic agent.

11. A method of treating cancer in a patient comprising  
5 administering to the patient a molecule which downregulates expression or activity of Lng108.

Sub B2 } 12. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10  
or 11 wherein the cancer is lung cancer.

13. A method of inducing an immune response against a  
10 target cell expressing Lng108 comprising delivering to a human patient an immunogenically stimulatory amount of a Lng108 protein so that an immune response is mounted against the target cell.

14. A vaccine for treating cancer comprising an  
15 immunogenically stimulating amount of Lng108.